Indomethacin Dosage Recommendations
For acute gout in adults, start with 50 mg three times daily until pain is tolerable, then rapidly reduce to complete cessation; for chronic rheumatoid arthritis, use 25-50 mg two to three times daily with a maximum of 200 mg/day; for patent ductus arteriosus (PDA) closure in preterm infants, use the standard intravenous regimen of 0.2 mg/kg every 12 hours for 3 doses. 1, 2
Adult Dosing
Acute Gout
- Initial dose: 50 mg three times daily (150 mg/day total)
- Continue until pain is tolerable, then rapidly taper and discontinue
- Most patients show ≥50% improvement within 24 hours 3
- The 2020 ACR gout guideline recommends NSAIDs as one option for anti-inflammatory prophylaxis when initiating urate-lowering therapy, though it does not specify indomethacin dosing 4
Chronic Rheumatoid Arthritis
- Starting dose: 25 mg two to three times daily (50-75 mg/day)
- Maintenance: Increase by 25-50 mg increments at weekly intervals
- Maximum: 200 mg/day
- Take with food to minimize GI effects 1, 2
Key pharmacokinetic considerations: Indomethacin reaches peak plasma concentrations at approximately 2 hours, has a half-life of 4.5 hours, and is virtually 100% bioavailable orally. Steady-state concentrations are 1.4 times higher than first-dose levels with regular dosing 1, 2.
Pediatric Dosing for Patent Ductus Arteriosus
Standard Intravenous Regimen (Recommended)
The standard dose of 0.2 mg/kg IV every 12 hours for 3 doses should be used, as higher doses increase morbidity without improving closure rates.
- Dose: 0.2 mg/kg IV every 12 hours
- Course: 3 doses total
- Closure rate: 65-79% with standard dosing 5, 6
Critical Evidence Against High-Dose Regimens
High-dose indomethacin (0.5 mg/kg/day) is not recommended despite theoretical benefits. A 2021 study demonstrated that high-dose indomethacin significantly increased:
- Necrotizing enterocolitis (17% vs 7%, p=0.01)
- Bronchopulmonary dysplasia (79% vs 55%, p=0.02)
- Gastrointestinal hemorrhage (32.7% vs 11.7%, p=0.001)
- Retinopathy of prematurity (13.5% vs 2.6%, p=0.004) 7
A 2008 multicenter RCT confirmed that increasing doses from 0.1 to 0.2-0.5 mg/kg/day achieved 2.9-fold higher serum concentrations but failed to improve PDA closure (52% vs 45%, p=0.50) while significantly increasing serum creatinine >2 mg/dL (6% vs 19%, p<0.05) and moderate/severe ROP (15% vs 36%, p<0.025) 8.
Important Clinical Considerations
Monitoring Requirements
- Renal function: Check serum creatinine and urine output, especially in neonates (indomethacin can cause oliguria and azotemia)
- GI effects: Monitor for bleeding, especially with prolonged use
- Neonatal complications: Watch for NEC, IVH, and ROP in preterm infants
Common Pitfalls to Avoid
- Do not use high-dose regimens for PDA closure - the risk-benefit ratio is unfavorable 7
- Do not continue acute gout treatment beyond symptom resolution - rapid taper once tolerable
- Do not exceed 200 mg/day in adults - higher doses increase adverse effects without additional benefit 1, 2
- Do not ignore renal function - indomethacin is contraindicated in significant renal impairment
Alternative Considerations
For PDA closure, acetaminophen has emerged as an alternative with comparable efficacy (closure rates similar to indomethacin) but lower rates of necrotizing enterocolitis (RR 0.37,95% CI 0.14-0.95) and no post-treatment azotemia 9. High-dose oral ibuprofen (when available) may offer superior PDA closure rates compared to standard intravenous indomethacin 6.